What are the key considerations for biotech European expansion?

By Juan Salcines Gomez-Pardo, Consultant, Monitor Deloitte

Biotech

Small to medium sized life sciences companies are now at the forefront of innovation in the search for new cures and hope for patients. However, many biotech and medtech companies face significant challenges in navigating the business life cycle. Monitor Deloitte colleagues Li Xiaofeng, Hanno Ronte and James Forsyth have recently published our latest thinking on ‘Biotech-in-a-boxTM: ‘How to ‘ACE’ geographical expansion in Europe’. This report introduces a three-step game plan to support biotech and medtech companies to thrive in an increasingly challenging environment, de-risk attempts to scale up adoption of technologies and improve success in geographical expansion. This week’s blog by our colleague, Juan Salcines, highlights the key findings from this report, based on his recent experience working with biotech companies across Europe.

Continue reading

Posted on 21/02/2020 | 0 Comments

Intelligent clinical trials: Transforming through AI-enabled engagement

By Dr Francesca Properzi, PhD. Research Manager, and Maria João Cruz, Research Analyst, Centre for Health Solutions

Clinical-trial

This week we launched the third report in our series on the impact of artificial intelligence (AI) across the biopharma value chain. This latest report, Intelligent clinical trials: Transforming through AI-enabled engagement, explores how AI, in particular machine learning and natural language processing, can reduce clinical trial cycle times while reducing the costs and improving the productivity and outcomes of clinical development. In this blog, we highlight the main takeaways from our report.

Continue reading

Posted on 13/02/2020 | 0 Comments

Reflections on World Cancer Day 2020. I Am and I Will.

By Maria João Cruz, Research Analyst, Centre for Health Solutions

Hands

Tuesday, 4th February, was the 20th World Cancer Day, a day that unites people, communities and entire countries to raise awareness and take action to reduce the global burden and impact of cancer. This year marks the mid-point of a three year campaign, led by the Union for International Cancer Control (UICC), ‘I Am and I Will’. This campaign is seen as an empowering ‘call-to-action’, urging everyone to commit personally to taking action now to impact the future.1 Today, I want to share with you my reflections on the importance of this day.

Continue reading

Posted on 07/02/2020 | 0 Comments

Will Primary Care Networks be the engine of change to drive Integrated Care?

By Dr Jane Halpin and Dr Arvind Madan

Lshc

Since July 2019, as part of the NHS Long Term Plans (LTPs) ambition to develop integrated health and care, all general practices in England have come together to form one of 1,250 or so Primary Care Networks (PCNs). While this isn’t the first attempt to encourage greater cooperation between practices, it is the first time in NHS history that real terms funding for primary and community health services is guaranteed to grow at a faster rate than that of the overall NHS budget, including £1.8 billion to support the establishment of PCNs.

Continue reading

Posted on 31/01/2020 | 0 Comments

M&A in R&D: How innovative and unfamiliar acquisitions can unlock R&D productivity

By David Tullett, Consultant, Deloitte MCS Limited

Ma-blog-image

Earlier this month our colleagues published their report, The role of innovative and unfamiliar acquisitions in unlocking R&D productivity, which looks at the impact of M&A on the pharma landscape and outlines how external innovation is impacting pharmaceutical R&D and the reasons behind the projected growth in deal volume for 2020. This week’s blog by our colleague, David Tullett, who worked closely on the above report with Heena Dodhia and Mark Stockbridge, provides his view on the key takeaways.

Continue reading

Posted on 24/01/2020 | 0 Comments

2020 global life sciences outlook: Creating new value, building blocks for the future

By Dr Mark Steedman, PhD, Manager, Centre for Health Solutions

Ls-outlook

Each January, Deloitte produces a report exploring the outlook for the life sciences sector. This year’s report, 2020 global life sciences outlook: Creating new value, building blocks for the future, explores how biopharma and medtech organisations can harness a future driven by evolving data-driven technologies and remain relevant in an ever-evolving business landscape. Organisations should look for ways to create new value, adopt new metrics to take advantage of the wealth of data available today and rethink what is being measured.

Continue reading

Posted on 17/01/2020 | 0 Comments

Dry January: Is it time to reset your relationship with alcohol?

By Dr Mark Steedman, PhD, Manager, Centre for Health Solutions

Lights'

Happy 2020 everyone! The New Year and new resolutions often go hand in hand. A new year brings an opportunity for a fresh start, to transform bad habits into good habits or to start something entirely new. For many, this means exercising more, eating healthier foods, spending more time with family or going to sleep earlier, to name only a few common New Year’s resolutions. Increasingly in the UK, people are starting month-long challenges during January to kick-start their resolutions and attempt to create better long-term habits. Dry January is one of these challenges.

Continue reading

Posted on 10/01/2020 | 0 Comments

Ten years on: Measuring the return from pharmaceutical innovation 2019

By Maria João Cruz, Research Analyst, Centre for Health Solutions

Pharma

This week, we published the tenth in our series of annual reports, Measuring the return from pharmaceutical innovation. For the past decade we have used a consistent and objective methodology to provide analyses and insights on the R&D productivity of the top 12 biopharma companies (original cohort), and the returns they can expect to achieve from their late stage pipelines. For five years, we have contrasted our original cohort’s performance with the performance of four smaller, more specialised companies, which we tracked back to 2013. While our findings have demonstrated a systemic, cross-company, decade-long decline in the productivity of R&D, we have also witnessed significant advances in science and the development of innovative therapies delivering impressive improvements in health outcomes.

Continue reading

Posted on 19/12/2019 | 0 Comments

Insights from our State of the State 2019-20 report: How health sector leaders and citizens view the outlook for NHS and social care services

By Karen Taylor, Director, Centre for Health Solutions

SOTS

So the results of the election are now in, and the Conservatives have won a large majority, giving them a mandate to get on with implementing their manifesto promises. During their electioneering, all parties put the NHS and social care at centre stage, with the only differences being how much additional funding and new staff they would provide to tackle the acknowledged decline in performance. In October 2019, my public sector colleagues, together with the think tank Reform, published their eighth annual report, The State of the State 2019-20 the view from citizens, leaders and frontline public services.1 Friday the 13th, the morning after the election, seems like a good time to remind the new Government and those charged with implementing their policies of the 2019 report findings, particularly their findings on the NHS and social care.

Continue reading

Posted on 13/12/2019 | 0 Comments

The FT Global Pharmaceutical and Biotechnology Conference 2019: Forces disrupting the industry

By Karen Taylor, Director, Centre for Health Solutions

Ftg

Last month Deloitte was one of the main sponsors of the 2019 FT Global Pharmaceutical and Biotechnology Conference. This is a key event for the industry, attended by senior industry executives and financial professionals from around the world. The aim of this year’s conference was to focus a critical eye on the forces set to transform the industry in the years ahead. I was privileged to attend the conference and help man our stall where we displayed our research reports, including our report Intelligent biopharma: Powered by AI, which we launched on the first day. We also introduced our new Converge Health platform and the connected patient experience. This week’s blog shares some of the highlights that I took away from the presentations and panel debates that took place on the first day. I will return to day two in a later blog.

Continue reading

Posted on 06/12/2019 | 0 Comments

2019 Global Survey of health care consumers: United Kingdom cut

By Karen Taylor and Krissie Ferris, Centre for Health Solutions

Global Health Care Trends Survey

Since 2008, the Deloitte US Center for Health Solutions has polled a nationally representative sample of US adults (18 and older) about their experiences and attitudes related to their health, health insurance, and health care.1 Earlier this year we helped the US Center design a global survey to help understand what consumers value most about healthcare, and their appetite for digital innovations, including their willingness to share their personal health data. The US Center collected primary data through an online survey, fielded between May and June 2019, in seven countries (Australia, Canada, Denmark, Germany, Netherlands Singapore and the UK). It then compared their responses to responses from the US consumer survey conducted in 2018. The US Centre launched their report on the survey last week.2 This week’s blog is our take on the key findings for the UK.

Continue reading

Posted on 28/11/2019 | 0 Comments